Cargando…

Severity of BA.2 variant and vaccine effectiveness against symptomatic disease in Scotland

Detalles Bibliográficos
Autores principales:	Kerr, Steven, Robertson, Chris, Hillman, Sam, Grange, Zoe, Sullivan, Christopher, Sheikh, Aziz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635838/ https://www.ncbi.nlm.nih.gov/pubmed/36373099 http://dx.doi.org/10.1016/j.lanepe.2022.100533

Ejemplares similares

Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland
por: Robertson, Chris, et al.
Publicado: (2023)

Characterising adults in Scotland who are not vaccinated against COVID-19
por: Hameed, Safraj Shahul, et al.
Publicado: (2022)

Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design
por: Sheikh, Aziz, et al.
Publicado: (2022)

Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland
por: Grange, Zoe, et al.
Publicado: (2021)

COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland
por: Kerr, Steven, et al.
Publicado: (2022)

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
por: Sheikh, Aziz, et al.
Publicado: (2021)

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant
por: Sheikh, Aziz, et al.
Publicado: (2021)

Uptake of monoclonal antibodies and antiviral therapies for COVID-19 in Scotland
por: Tibble, Holly, et al.
Publicado: (2023)

Moving towards a precision approach for prevention of severe COVID-19 – Authors' reply
por: Agrawal, Utkarsh, et al.
Publicado: (2023)

Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
por: Florentino, Pilar T V, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
por: Huo, Jiandong, et al.
Publicado: (2022)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection
por: Chen, Xiaosu, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
por: Tartof, Sara Y, et al.
Publicado: (2022)

BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era
por: Shah, Syed Ahmar, et al.
Publicado: (2022)

Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa
por: Wolter, Nicole, et al.
Publicado: (2022)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
por: Evans, John P., et al.
Publicado: (2022)

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months
por: Malato, João, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
por: Rudan, Igor, et al.
Publicado: (2022)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients
por: Alcheikh, Ahmad, et al.
Publicado: (2023)

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
por: Rahimi, Farid, et al.
Publicado: (2022)

Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
por: Vatteroni, Maria Linda, et al.
Publicado: (2022)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Emergence of Omicron sub-variant BA.2: Is it a matter of concern amid the COVID-19 pandemic?
por: Dhawan, Manish, et al.
Publicado: (2022)

Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants
por: Malato, João, et al.
Publicado: (2022)

Effects of lockdown on retinal detachment incidence in Scotland
por: Shams, Fatemeh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_06fk5mkhaorg3rkr5mkje1oqrn